Immunotherapy Advances 2022 Editors' Choice Virtual Issue

Figure from Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer
Figure from 'Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer'

In this collection, our official journal Immunotherapy Advances presents some of the standout articles from 2022, hand-picked by our Editor-in-Chief, Professor Tim Elliott.

These Open Access articles cover the full breadth of immunotherapy research from bench to bedside, including the engineering of antibodies, identification of immunological targets and the latest clinical trials exploring therapeutics for allergy and autoimmune diseases. 

We hope you enjoy this selection of papers and we encourage you to spread the word by sharing this free collection of articles with your network. If you’re on Twitter, don’t forget to tag us @IMTadvances.

Advanced cell therapy

Review

Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy

Dayane Schmidt, Sima Ebrahimabadi, Kauan Ribeiro de Sena Gomes, Graziela de Moura Aguiar et al.

Review

Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer

Rafaela Rossetti, Heloísa Brand, Sarah Caroline Gomes Lima, Izadora Peter Furtado et al.

Figure from 'Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors'
Figure from 'Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors'

New insights into immunomodulatory targets in cancer

Review

Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity

Stephanie E A Burnell, Lorenzo Capitani, Bruce J MacLachlan et al.

Research Article

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor

Stephanie Schwartz, Nidhi Patel, Tyler Longmire, Pushpa Jayaraman

Commentary

TIM-3: a tumor-associated antigen beyond checkpoint inhibition?

Stefan Barth, Krupa Naran

Review

Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors

Guilherme Ferreira de Britto Evangelista, Amanda Braga Figueiredo, Milton José de Barros e Silva, Kenneth J Gollob

Targets that span multiple diseases

Review

Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer

Tosca Holtrop, Kevin Budding, Arianne M Brandsma, Jeanette H W Leusen

New insights into immunotherapy of allergy

Review

New and emerging concepts and therapies for the treatment of food allergy

David W Hwang, Cathryn R Nagler, Christina E Ciaccio

Review

Immunology of allergen immunotherapy

Rifat S Rahman, Duane R Wesemann

TrialsWatch

Peanut oral immunotherapy: current trends in clinical trials

Simone Reinwald, Jennifer M Rolland, Robyn E O’Hehir, Menno C van Zelm

Immunotherapy in type 1 diabetes

Research article

A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes

Ashish K Marwaha, Samuel Chow, Anne M Pesenacker et al.

 

Immunotherapy Advances  welcomes original research, reviews, commentaries and TrialsWatch articles addressing a range of topics that contribute to our understanding of the immunotherapeutic treatment options for asthma and allergies.